ビスペシフィック抗体グローフィタマブによる分散型大B細胞リンパ腫と抗合成症候群の治療に成功
Chong Wei1, Mei Zhang2, Danqing Zhao1
1Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Cancer management and research
|September 3, 2025
まとめ
双特定抗体であるグロフィタマブは,再発性拡散型B細胞リンパ腫 (DLBCL) と耐性抗合成酵素症候群 (ASyS) の症状を効果的に治療しました. これは,血液学的悪性腫瘍と自己免疫疾患の両方の二重の可能性を強調しています.
科学分野:
- 腫瘍学
- 免疫学
- リウマトロジ
背景:
- グロフィタマブ (CD20×CD3) のような二固有の抗体は,B細胞悪性腫瘍の新興治療法である.
- 共通のB細胞経路があるため,自己免疫疾患に対する応用が注目されています.
- 拡散型B細胞リンパ腫 (DLBCL) と抗合成酵素症候群 (ASyS) は,しばしば複雑な治療を必要とする異なる疾患です.
研究 の 目的:
- 併存した抗合成酵素症候群 (ASyS) の患者に拡散性B細胞リンパ腫 (DLBCL) の症例を報告する.
- 耐火性DLBCLおよび併発性ASySの治療におけるグローフィタマブの有効性を評価する.
- 自己免疫症状の管理におけるT細胞誘導バイスペシフィック抗体の可能性を調査する.
主な方法:
- 耐火性DLBCLとASySの患者は,グローフィタマブによる第3線治療を受けた.
- 以前の治療には,R- CHOP,レナリドミドとポラツムラブベドチン,ASySに対する複数の免疫抑制剤/標的薬が含まれていました.
- リンパ腫の臨床寛解とASyS症状の解消をモニターした.
主要な成果:
- 患者さんはグローフィタマブ治療でDLBCLの完全寛解を達成しました.
- 驚くべきことに,耐性ASySの症状はリンパ腫治療と同時に解消した.
- グロフィタマブは,耐性DLBCLとASySの両方の患者に有効性を示した.
結論:
- グロフィタマブは,再発性/耐性DLBCLに対する有望な治療法です.
- このケースは,血性悪性腫瘍と共に,自己免疫的症状の治療のための新しい戦略を提供することを示唆しています.
- 自身免疫疾患に対するグローフィタマブのさらなる調査が必要である.
関連する概念動画
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K


